Answers are grounded in this paper and cite their sources.
Chronic allograft injury and progressive loss of graft function remain major challenges after kidney transplantation. Urinary transferrin has been proposed as an early marker of renal damage in diabetic nephropathy and chronic kidney disease, but its clinical utility in kidney transplant recipients (KTRs) is unclear. We conducted an observational study of 50 adult KTRs who provided a spot urine sample. Thirty recipients had reduced allograft function (estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m 2 ) at sampling, and 20 served as controls. Urinary transferrin was quantified by proteomics and enzyme-linked immunosorbent assay, and normalized to urinary creatinine (urinary transferrin/creatinine ratio, uTf/Cr). Rapid renal function decline was defined as an annualized eGFR decline greater than 3 mL/min/1.73 m 2 /year or initiation of dialysis. uTf/Cr correlated positively with serum creatinine at sampling (r = 0.29, P = 0.038) and inversely with eGFR at sampling (r = −0.28, P = 0.050). uTf/Cr was higher in recipients with reduced allograft function than controls (9.2 ± 8.0 vs 4.0 ± 3.3, P = 0.003) and discriminated reduced allograft function with an AUC of 0.753 (95% CI 0.615–0.891) in ROC curves. Rapid renal function decline occurred in 19 recipients (38.0%). uTf/Cr was higher in the rapid renal function decline group than in the stable group (11.6 ± 8.8 vs 4.3 ± 3.6, P = 0.002), with an AUC of 0.832 (95% CI 0.722–0.942). In univariable logistic regression, uTf/Cr was associated with rapid renal function decline (odds ratio [OR] 1.30; 95% CI 1.10–1.53; P = 0.002) and remained significant after multivariable adjustment (OR 1.19; 95% CI 1.02–1.47; P = 0.019). Higher uTf/Cr was also associated with faster annualized eGFR decline (r = −0.47, P = 0.001). In conclusion, urinary Tf/Cr is associated with reduced allograft function and rapid renal function decline in KTRs. These findings support further validation of urinary transferrin as a non-invasive biomarker for contemporaneous and longitudinal allograft dysfunction in KTRs.
No takes yet. Share an insight, caveat, or question.
Huh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: